ADTX Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PARDAVIMAS 107991 min ago

@ $4.00

Išleistas: 13 vas. 2024 @ 21:29

Grąža: -40.25%

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

Stats
Šios dienos apimtis	65 262.00
Vidutinė apimtis	372 577
Rinkos kapitalizacija	4.69M
EPS	$0 ( 2024-04-02 )
Kita pelno data	( $-3.33 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0200
ATR14	$0.0500 (2.08%)

Insider Trading

Date	Person	Action	Amount	type
2023-11-08	Runge Jeffrey W.	Buy	470	Options (right to buy)
2023-11-08	Albanna Rowena	Buy	4 702	Options (right to buy)
2023-11-08	Nelson Charles Athle	Buy	470	Options (right to buy)
2023-11-08	Albanna Amro A.	Buy	9 404	Options (right to buy)
2023-11-08	Pankovcin Corinne	Buy	4 702	Options (right to buy)

INSIDER POWER
26.52
Last 84 transactions
Buy: 1 934 500 \| Sell: 1 185 103

Tūris Koreliacija

Ilgas: 0.10 (neutral)

Trumpas: -0.80 (moderate negative)

Signal:(42.192) Neutral

ADiTx Therapeutics, Inc. Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
OGI	0.974
BNGO	0.971
VERB	0.971
CNXC	0.968
IMBI	0.965
NESR	0.965
MRIN	0.964
WATT	0.963
MMAT	0.962
DISH	0.961

10 Labiausiai neigiamai susiję koreliacijos
MSDA	-0.971
ADAL	-0.966
TIOAU	-0.961
TIOA	-0.961
BRIV	-0.96
LEGA	-0.959
ZING	-0.959
SKYA	-0.958
CRZN	-0.957
VLAT	-0.957

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

ADiTx Therapeutics, Inc. Koreliacija - Valiuta/Žaliavos

0.65
( weak )

0.62
( weak )

0.00
( neutral )

0.55
( weak )

-0.26
( neutral )

-0.46
( neutral )

ADiTx Therapeutics, Inc. Finansinės ataskaitos

Annual	2023
Pajamos:	$645 176
Bruto pelnas:	$-654 243 (-101.41 %)
EPS:	$-107.10

FY	2023
Pajamos:	$645 176
Bruto pelnas:	$-654 243 (-101.41 %)
EPS:	$-107.10

FY	2022
Pajamos:	$933 715
Bruto pelnas:	$166 936 (17.88 %)
EPS:	$-608.04

FY	2021
Pajamos:	$105 034
Bruto pelnas:	$27 055.00 (25.76 %)
EPS:	$-6.72

Financial Reports:

No articles found.

ADiTx Therapeutics, Inc.

Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.